Management of the gastrointestinal system bleeding caused by direct-acting oral anticoagulants.

Arterial and venous thromboembolism is a common and serious clinical condition where anticoagulation is administered for its treatment and prophylaxis. Anticoagulants prevent the formation of new thrombi and thus the extension of the existing thrombus. Direct-acting oral anticoagulants (DOAC) include dabigatran, which is a thrombin inhibitor, and rivaroxaban, apixaban, and edoxaban, which are anti-Xa agents. These are administered in the secondary prophylaxis and treatment of various diseases of thrombus. Although it is specified that they reduce the risk of bleeding due to all causes, many important studies have also reported that they increase the risk of gastrointestinal system (GIS) bleeding. Therefore, similar to Vitamin K antagonists (VKA), their use is contraindicated in active bleeding, active ulcers, hemorrhagic angiodysplasia, and recurrent bleeding requiring recurrent transfusion. However, these contraindications are mostly transient. We aimed to analyse the risk, prophylaxis and management of the active GIS bleeding in patients taking DOAC in this article. [ABSTRACT FROM AUTHOR]